These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15166029)

  • 1. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
    Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
    Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
    Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
    Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
    Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
    Levis M; Murphy KM; Pham R; Kim KT; Stine A; Li L; McNiece I; Smith BD; Small D
    Blood; 2005 Jul; 106(2):673-80. PubMed ID: 15797998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
    Zheng R; Friedman AD; Small D
    Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3/ITD mutation signaling includes suppression of SHP-1.
    Chen P; Levis M; Brown P; Kim KT; Allebach J; Small D
    J Biol Chem; 2005 Feb; 280(7):5361-9. PubMed ID: 15574429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
    Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
    Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.
    Kim KT; Baird K; Ahn JY; Meltzer P; Lilly M; Levis M; Small D
    Blood; 2005 Feb; 105(4):1759-67. PubMed ID: 15498859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
    Levis M; Pham R; Smith BD; Small D
    Blood; 2004 Aug; 104(4):1145-50. PubMed ID: 15126317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
    Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
    Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
    Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
    Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
    Levis M; Tse KF; Smith BD; Garrett E; Small D
    Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.